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Roles of tumor suppressors in regulating
tumor-associated inflammation
L Yang*,1 and M Karin*,2
Loss or silencing of tumor suppressors (TSs) promotes neoplastic transformation and malignant progression. To date, most
work on TS has focused on their cell autonomous effects. Recent evidence, however, demonstrates an important noncell
autonomous role for TS in the control of tumor-associated inflammation. We review evidence from clinical data sets and mouse
model studies demonstrating enhanced inflammation and altered tumor microenvironment (TME) upon TS inactivation.
We discuss clinical correlations between tumor-associated inflammation and inactivation of TS, and their therapeutic
implications. This review sets forth the concept that TS can also suppress tumor-associated inflammation, a concept that
provides new insights into tumor–host interactions. We also propose that in some cases the loss of TS function in cancer can be
overcome through inhibition of the resulting inflammatory response, regardless whether it is a direct or an indirect consequence
of TS loss.
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Facts
 p53 mutations were documented in over 50% of human
cancers. Loss of normal p53 function is frequently
associated with an increased susceptibility to inflamma-
some-driven cancers such as ulcerative colitis-associated
colorectal cancer.
 In mouse cancer models of solid cancer, p53 mutations
can cause chronic inflammation and persistent tissue
damage.
 Loss of adenomatous polyposis coli (APC) in human
and mouse colon cancer is associated with enhanced
infiltration of early adenomas by microbial products that
elicit a tumor-associated inflammatory response by an
upregulation of interleukin (IL)-17 that drives malignant
progression.
 Studies using mouse models reveal that loss of TGFb
signaling in cancer epithelial cells results in increased
infiltration of inflammatory cells into the tumor microenvir-
onment (TME).
 Metformin, a widely prescribed antidiabetic drug with anti-
inflammatory properties, is found to decrease the incidence
of several malignancies including breast and pancreatic
cancers.
Open Questions
 Does inflammation have a critical role in p53 gain-of-
function?
 Does loss of tumor suppressor (TS) function result in the
direct induction of inflammatory cytokines and chemokines
or does it cause this effect due to enhanced tissue
damage?
 Would inhibition of tumor-associated inflammation
provide an effective mean to overcome the loss of TS
function?
TS are powerful transcriptional and signaling regulators that
negatively modulate cell proliferation and survival. As such,
TS counteract the growth promoting activity of oncogenes
mainly through cell autonomous mechanisms. As amply
described elsewhere,1 the major properties of classic TS
genes are: (1) they are recessive and undergo biallellic
inactivation in tumors; (2) inheritance of a single mutant allele
increases cancer susceptibility as reflected by the autoso-
mally dominant pattern of familial cancer syndromes; (3) TS
genes are frequently inactivated in sporadic cancers. In
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addition to cell cycle progression and cell survival, TS regulate
the detection and repair of DNA damage, protein turnover,
autophagy, and metabolism. This review examines and
discusses effects of TS on the interaction between the
malignant cells and their microenvironment, a little studied
aspect of TS function. We present evidence from mouse
models and clinical studies that some TS also control tumor-
elicited inflammation and will discuss potential mechanisms
underlying this function. We hope that this review will lead to
new thinking regarding the nonautonomous function of TS as
negative regulator of inflammation. Accordingly, we suggest
that anti-inflammatory therapies may partially compensate for
loss of TS function in cancer.
TS as Regulators of Tumor-Associated Inflammation
We postulate that one consequence of TS loss (Figure 1,
input, black arrows), is elevated expression of growth factors,
cytokines, and chemokines, which induce the recruitment,
infiltration, and activation of host-derived inflammatory and
stromal cells (Figure 1, mechanisms, in the big center circle).
Once present within the tumor, these cells promote sustained
cancer cell proliferation, evasion of apoptosis, replicative
immortality, dysregulation of metabolism, invasion and
metastasis, and genomic instability through a variety of
noncell autonomous mechanisms (Figure 1, output, blue
arrows). Collectively, these events create a pro-tumorigenic
microenvironment that is immune suppressive and vascular
permissive. Key studies supporting this hypothesis are listed
in Table 1. It should be noted that it is not easy to distinguish
the consequence of direct induction of inflammatory cytokines
due to loss of TS function and induction of inflammatory
cytokines during the tissue damage response that can also be
triggered upon TS loss. It is perceivable that the two effects go
hand in hand and that their actions are intertwined during
tumor progression. For example, chronic inflammation asso-
ciated with infection, autoimmune disease, prolonged expo-
sure to environmental irritants or obesity precedes tumor
development and can cause genomic instability, DNA
damage, loss of TS function, early tumor promotion, and
enhanced angiogenesis. The direct induction of inflammatory
cytokines due to loss of TS function can further drive more
tissue and cell damage associated with tumor initiation and
progression.
p53. p53, the most extensively studied TS, provides a potent
roadblock to tumorigenesis, and its loss has been documen-
ted in over 50% of human cancers. Mutant forms of p53
cannot cause cell cycle arrest and/or apoptotic cell death, no
longer maintain genomic integrity, and fail to induce expres-
sion of metabolic regulators.2,3 Clinical evidence suggests
that p53 inactivation or deletion induces inflammation. For
example, p53 is frequently mutated in ulcerative colitis-
associated dysplastic lesions and colorectal cancer.4,5 The
increased frequency of p53 mutations in noncancerous
ulcerative colitis epithelial cells may confer susceptibility to
the development of colorectal cancer by enhancing the
accumulation of nitric oxide (NO).6 In addition, a study of 833
patients with primary breast carcinoma revealed a strong
association between p53 mutations and increased vascular
endothelial growth factor (VEGF) expression.7 VEGF family
members are expressed by tumor-infiltrating macro-
phages.8,9 A study of head and neck squamous cell
carcinoma (HNSCC) suggested that p53 suppresses inflam-
mation through effects on NF-kB transcriptional activity.10
In mouse models, p53 mutations induce inflammation, bile
duct injury, and fibrosis, which resemble the pathology of
intrahepatic cholangiocarcinoma, a lethal human malignancy
of the biliary epithelium, in which loss of p53 function is
frequently observed.11 Mutant p53 forms (p53G515A or
p53R172H) prolong TNF-induced NF-kB activation in cultured
cells.12 As NF-kB contributes to elevated expression of
inducible NO synthase (iNOS),13 this may explain the link
between p53mutations and NO accumulation. Even germ line
p53 mutations can lead to chronic colonic inflammation and
persistent tissue damage, thereby mimicking features of
human colitis-associated colorectal cancer.12 In addition,
p53 deletion induced an inflammatory microenvironment with
elevated NO that accelerates spontaneous lymphoma devel-
opment.14 In a mouse prostate cancer (PCa) model, loss of
p53 results in enhanced transcription of cytokine and
chemokine genes, accumulation of reactive oxygen species
(ROS) and protein oxidation products, enhancedmacrophage
activation and neutrophil clearance, as well as high expres-
sion of inflammation markers.15 Combined loss of p53 and
ATR, an essential factor in genome maintenance and DNA
repair, leads to severe defects in hair follicle regeneration and
deterioration of the intestinal epithelium, associated with
tumor infiltration with inflammatory Mac1þGr1þ cells.16
Specific p53 ablation in the intestinal epithelium resulted in
increased permeability, leading to formation of an NF-kB-
dependent inflammatory microenvironment and epithelial–
mesenchymal transition.17 This effect is independent of the
well-established role of p53 in cell cycle regulation, apoptosis,
and senescence. More recently, ablation of p53 in hepatic
Figure 1 TS regulate the inflammatory microenvironment: loss of TS (input,
black arrows), including p53, TGFb, APC, and PTEN, increases expression of
growth factors, cytokines, and chemokines, which induce infiltration of host-derived
inflammatory and stromal cells (mechanisms, in the big center circle). These cells in
turn promote sustained proliferation, evasion of apoptosis, replicative immortality,
dysregulation of metabolism, invasion, metastasis, and genomic instability (output,
blue arrows)
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stellate cells (HSCs) was found to increase liver fibrosis, and
accelerate transformation of adjacent hepatocytes in a
noncell autonomous manner involving macrophage polar-
ization.18 Although p53 mutations were never found to occur
in HSC or other types of nontransformed cells, these findings
suggest a noncell autonomous function of p53 in the TME
that can be manifested upon downregulation of p53 expres-
sion on account of gene methylation or other mechanisms.
Reactivation of endogenous p53 in p53-deficient tumors in a
mouse model of hepatocellular carcinoma (HCC) can cause
complete tumor regressions.19 The underlying mechanism
does not seem to depend on apoptosis, and instead may
involve the induction of a cellular senescence program
that is associated with upregulation of certain inflammatory
cytokines.19
Mutant forms of p53 exhibit different modes of action.20
Whereas most mutants exhibit loss-of-TS functions, certain
p53 mutants have gained oncogenic activity.21 Often, mutant
p53 can antagonize the TS function of WT p53 in a dominant
negative manner. Such a situation, however, is often
transient, and is frequently followed by loss of heterozygosity
(LOH) during cancer progression.20 Interestingly, gain-of-
function p53 mutants, such as p53R273H, was found capable
of NF-kB activation and can therefore induce tissue damage
and chronic inflammation that promotes tumor develop-
ment.12 These studies suggest that ability to induce inflam-
mation is an important property that contributes to the
oncogenic function of such p53 mutants. Two other members
of the p53 family, p63 and p73, are also involved in the
regulation of inflammation and cancer development.22–24 In
summary, we suggest that the ability of WT p53 to inhibit
tumor-associated inflammation should be added to the list of
its tumor-suppressive activities.25
APC (adenomatous polyposis coli). The APC tumor
suppressor is particularly important in regulation of gut
epithelial cell proliferation, adhesion, and migration. Germ
line allelic loss of APC is a hallmark of human familial
adenomatous polyposis syndrome as well as sporadic
colorectal cancer. Studies suggest a strong correlation
between colon cancer progression and tumor-associated
inflammation.26,27 Colorectal tumors exhibit immune/inflam-
matory infiltrates and inflammatory gene signature. In fact the
type, density, and location of immune cells within human
colorectal tumors predict clinical outcome. Although CD4þ
TH1 cells and CD8þ cytotoxic T cells (CTL) constitute a
positive prognostic sign in human colorectal cancer,28
myeloid cells and T-helper IL-17-producing cells promote
tumor progression.27 A clinical study demonstrated that
upregulation of IL-17 negatively correlates with patient
survival.29 As APC is a hallmark of colon cancer, these
clinical studies suggest a likely association between APC
deficiency and inflammation. Indeed, mouse model studies
strongly support this link. For example, mono-allelic deletion
of Apc in mouse intestinal epithelial cells (Apcþ /D) results in
tumor development upon inactivation of the WT Apc allele
due to LOH.30–32 When Apcþ /D mice are crossed with
transgenic mice expressing constitutively active IkB kinase b
(IKKb) in intestinal epithelial cells (IECs), the compound mice
exhibit more b-catenin positive (þ ) early lesions and small
intestinal and colonic tumors relative to the parental Apcþ /D
line, and their survival is compromised.13 Accelerated
tumorigenesis in this model is due to elevated expression
of iNOS, leading to the formation of oxidative DNA lesions.
Treatment of compound mice with an iNOS inhibitor
decreased DNA damage markers and reduced early
b-catenin (þ ) lesions and tumor load.13 Importantly, APC
Table 1 Evidence for tumor suppressors that function as inflammation suppressors
Tumor
suppressor
Alterations Mouse models Inflammation and tumor microenvironment
change
References
p53 Mutation in biliary epithelium Intrahepatic
cholangiocarcinoma
Inflammation and fibrotic matrix
microenvironment
Farazi et al109
Deletion in intestinal epithelial
cells
Carcinogenesis of colorectal
cancer
NF-kB-dependent inflammatory
microenvironment
Schwitalla
et al110
Deletion in hepatic stellate cells Hepatocellular carcinoma Enhanced M2 microenvironment Lujambio
et al111
RB Deletion in prostate epithelium Prostatic intraepithelial
neoplasia
Increased stromal fibroblast proliferation Hill et al112
Germ line mutation Pituitary tumors Increased VEGF level and vessel dilation Chien et al113
APC APC allelic loss mediated by
Cdx2 cre
Colorectal cancer
development
Induction of IL-23 and IL-17 Grivennikov
et al114
PTEN Pten deletion in KRAS trans-
genic mice
Pancreatic ductal
adenocarcinoma
Activated NF-kB cytokine network and stromal
cells
Ying et al115
Tgfbr1/Pten double deletion in
epithelium
Head and neck squamous
cell carcinoma
Increased immune cell infiltration, angiogenesis,
NF-kB activation
Bian et al116
In stromal fibroblasts Mammary tumor
progression
ECM remodeling, immune cell infiltration, and
increased angiogenesis
Trimboli
et al117
TbRII TbRII deletion in mammary
epithelium
MMTV PyMT mammary
tumor
Enhanced myeloid cell infiltration and
metastasis
Yang et al118
Smad4 TbRII deletion in a number of
cancer epithelium
Colon, pancreatic, intestine
etc
Increased inflammatory cell infiltration and
tumor progression
Reviewed by
Yang119
Deletion in stromal fibroblast SCC in the forestomack Inflammation, DNA damage, loss of p15, p16,
p21
Achyut et al120
Smad 4 allelic loss in ApcD716
mutant mice
Invasive colorectal cancer Infiltration of CCR1 positive myeloid cells Kitamura
et al121
Deletion in T cells Epithelium cancer through
GI track
Massive inflammation Kim et al122
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deficiency also induces upregulation of inflammatory cyto-
kines. In a mouse model (CPC-APC) of colorectal tumor-
igenesis, in which Apc allelic loss is driven by Cdx2-Cre
transgene, the resulting colorectal tumors exhibited upregu-
lation of several proinflammatory cytokines, including IL-23
and IL-17A.33 IL-23 is expressed in tumor-infiltrating myeloid
cells in response to invasion of the APC-deficient adenomas
by microbial products.33 In turn, IL-23 induces the production
of IL-17 by T cells and innate lymphoid cells leading to
accelerated tumor growth and progression upon activation of
IL-17 receptor A. Loss of Apc in this model (which is also due
to LOH) results in rapid epithelial barrier deterioration, thus
providing a major impetus for tumor-elicited inflammation.33
Furthermore, epithelial barrier disruption and signs of
microbial invasion were also detected in human colorectal
tumors,33 in which elevated IL-17 expression is a particularly
bad prognostic sign.29 Another important inflammatory
mediator is cyclooxygenase 2 (COX-2), which is critical for
production of prostaglandin E2 that promotes neoplastic
transformation of gut epithelial cells. Non-steroidal anti-
inflammatory drugs (NSAIDs) such as aspirin show strong
preventive effect and were recently proposed as an adjuvant
therapy for colorectal cancer.34
PTEN (phosphatase and tensin homolog). PTEN is a
major TS that possesses dual lipid and protein phospha-
tase activity, and negatively regulates the pro-tumorigenic
PI3K–AKT pathway.35,36 A correlation between PTEN
inactivation and tumor inflammation has not been carefully
investigated. However, human HNSCC, are often deficient
in PTEN, and show infiltration of inflammatory monocytes,
angiogenesis and NF-kB activation, which were recapitu-
lated in mice deficient in Pten and Tgfbr1.37 It should be
noted, however, that loss of Tgfbr1 can also contribute to
the inflammatory response seen in these mice. In addition,
PTEN deficiency was reported to promote activation of the
NF-kB network in a mouse model of pancreatic ductal
adenocarcinoma driven by oncogenic KRAS, with accom-
panying stromal activation and immune cell infiltration.38 In
addition to PTEN deficiency in epithelial cells, a number of
recent studies suggest an important role of PTEN in
stromal fibroblasts in regulation of the TME in breast
cancer,39 further discussed below.
Collectively, such findings suggest that classical TS also
function as negative regulators of inflammation. Their dele-
tion, mutation or downregulation promotes the development of
an inflammatory TME. Chronic and localized inflammation is
one of the hallmarks of the cancer,40 and is a critical
participant in tumor initiation and progression. Different from
acute inflammation that can clear infection, heal wounds, and
maintain tissue homeostasis, tumor-associated inflammation
is often low in grade and chronic. Tumor-infiltrating inflamma-
tory cells, together with an abundance of cancer-associated
fibroblasts (CAFs) and endothelial progenitor cells (EPCs)
create a microenvironment that favors tumor progression by
providing growth factors, pro-angiogenic factors, proteases,
and adhesion molecules.26,41,42 The inflammatory microen-
vironment also provides a selective pressure for emergence
of malignant cell variants by enhancing genomic instability
and heterogeneity, and epigenetic alterations.43
Downregulation of TS Activities in Stromal Fibroblasts
CAFs have important tumorigenic functions.44 In invasive
human breast carcinomas, tumor-infiltrating CAFs produce
SDF-1/CXCL12, which signals through its cognate receptor,
CXCR4 onmalignant cells to promote tumor growth, invasion,
and angiogenesis.45 Gene expression signatures of the tumor
stroma can predict clinical outcome in breast cancer.46
Epithelial and stromal cell signaling influence one another,
and may co-evolve during the course of tumor progression.39
The dependence of tumors on stromal cells is also well
echoed in lymphoma and multiple myeloma. Despite accu-
mulation of numerous genetic alterations, the long-term
culture of early-stage tumor cells without a stromal support
is rarely successful. In a mouse model of B-cell lymphoma,
Hedgehog ligands are secreted by stromal cells and function
as survival factors for malignant progression through down-
regulation of Bcl2 in tumor cells.47 Another such factor is B-cell
activating factor (BAFF), which is produced by nurse-like
cells, specialized stromal cells that reside in the bonemarrow.
BAFF enhances chronic lymphocytic leukemia cell expression
of c-MYC by activating canonical IKK/NF-kB signaling.48
Although mutations in TS genes were reported to occur
within nonmalignant TME cells, including CAFs, such findings
remain highly controversial.49 A few clinical studies reported
p53 mutations in the stromal compartment of breast
cancer,50,51 but subsequent studies failed to reproduce these
results.52,53 Nevertheless, stromal-specific downregulation of
TS gene expression or function could contribute to the
malignant progression of epithelial tumors. Experimental
approaches using mouse models in which TS genes have
been inactivated in stromal cells show what can happen when
TS are downregulated in nontransformed cells. Curiously,
loss of p53 in stromal fibroblasts was found to result in loss of
p53 in PCa cells.54 Loss of PTEN in stromal fibroblasts, leads
to an increased PCa cell proliferation and inflammatory cell
infiltration.55 In amammary cancer model, genetic inactivation
of PTEN in stromal cells increased expression, phosphoryla-
tion and recruitment of Ets2, and accelerated the transforma-
tion of mammary epithelial cells, resulting in tumors with
extracellular matrix (ECM) remodeling, inflammatory infil-
trates, and increased angiogenic capacity.56 A PTEN-specific
signature was also observed in laser-captured human breast
cancer stroma.56 In addition, PTEN loss decreased expres-
sion of miR-320, a micro RNA that targets ETS2 mRNA. This
resulted in induction of an oncogenic secretome (for example,
matrix metalloproteinase-9, bone morphogenetic protein-1,
thrombospondin-1, and cathepsin B), that promotes tumor
angiogenesis and invasion.57 Deletion of TGFb type II
receptor (TGFbRII) in FSP1þ stromal cells (Tgfbr2fspKO)
contributes to epithelial transformation and results in devel-
opment of invasive squamous cell carcinoma in the mouse
forestomach.58,59 The underlying mechanisms include hepa-
tocyte growth factor,59 and altered p15, 16, and p21
expression mediated by inflammation-induced epigenetic
regulation.58,59 All of these studies support a general function
of TS in regulation of the TME. However, it should be noted
that the effect of stromal cells on the epithelial compartment of
tumors is context dependent. For example, loss of Rb1
and Trp53 in the lung epithelium activates the epithelial
TS suppresses tumor-associated inflammation
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cell-intrinsic Hedgehog signaling pathway and induces small-
cell lung cancer, independent of the lung microenvironment.60
Different results were also obtained in which TGFb signaling
in CAF was found to be essential for induction of chemokines
that recruit tumor-promoting B lymphocytes.61 The basis for
these marked discrepancies is currently unknown.
Anti-Inflammatory Mechanisms Involving TS
As illustrated above, deletion of TS genes in epithelial cells or
stromal fibroblasts can lead to induction of proinflammatory
and pro-tumorigenic gene transcription. Several transcription
factors are likely to be involved in this response, including NF-
kB, a key regulator of inflammation.26,62,63 However, the pro-
tumorigenic function of NF-kB is quite complex. Inactivation of
IKKb, a protein kinase needed for NF-kB activation, in IEC,
does not result in direct anti-inflammatory effect although it
prevents colitis-associated cancer by rendering IKKb-defi-
cient IECs susceptible to tumor-suppressive apoptosis.
Specific deletion of IKKb in myeloid cells, however, results
in a significant decrease in tumor growth by preventing the
production of proinflammatory cytokines that serve as growth
factors. Thus, specific inactivation of IKKb-dependent NF-kB
signaling in two different cell types can attenuate inflamma-
tion-driven tumorigenesis.64 In a mouse model of lung
adenocarcinoma, concomitant loss of p53 and expression of
oncogenic KRASG12D resulted in NF-kB activation, whereas
restoration of p53 expression led to NF-kB inhibition.65
Importantly, inhibition of NF-kB signaling induced apoptosis
in p53-null lung cancer cell lines and inhibited their tumori-
genic growth.65 NF-kB is a critical target for the inflammation
suppressive activity of p53.66 WT p53 and NF-kB antagonize
each other’s activities,66 and thus it is not surprising that p53
loss augments NF-kB activity. A recent study showed that
glucocorticoid-induced repression of NF-kB targeted gene
transcription was impaired upon p53 inactivation.67 LZAP, a
putative TS, lost inB30% of human HNSCC, can also inhibit
NF-kB, independently of ARF or p53.68 Components of the
NF-kB system can also interact with other TS. IKKa activation
in prostatic epithelial tumor cells, in response to lymphotoxin
(LT) or RANK ligand produced by tumor-infiltrating immune
cells, inhibits transcription of the metastasis suppressor
Maspin, thereby promoting metastatic progression.69,70 The
cylindromatosis protein (CYLD), functions as deubiquitinase
that removes lysine 63-linked ubiquitin chains from TRAF2,
thereby inhibiting NF-kB activation.71 The gene CYLD is
mutated in familial cylindromatosis, an autosomal dominant
disease characterized by benign tumors derived from cells of
skin appendages72 and thus it can be considered as a TS,
CYLD inhibits tumor cell proliferation by blocking BCL-3-
dependent NF-kB signaling.73 In the liver, however, disruption
of the Cyld gene affected tumor progression through the
protein kinases TAK1 and JNK.74
STAT3 is another important transcriptional regulator of
cancer-associated inflammation. STAT3 dimers, induced
upon phosphorylation by members of the JAK tyrosine kinase
family, enter the nucleus and activate a broad array of target
genes. STAT3 is activated in many cancers, including breast,
pancreatic, colon and liver, and its conditional ablation inhibits
cancer development and progression.75–79 Usually, STAT3 is
activated by a number of cytokines, including IL-6. However, a
number of nonconventional TS can negatively regulate
STAT3, and their inactivation augments STAT3-mediated
tumor-associated inflammation. For instance, deletion of
Ptpn11, a gene encoding the tyrosine phosphatases Shp2,
was found to promote STAT3 signaling resulting in liver
hyperplasia and tumor development.75 This result suggests a
TS function for Shp2 in hepatocellular carcinogenesis, yet
Ptpn11 mutations remain to be identified, although Shp2
enzymatic activity may be inhibited by ROS that accumulate
during tumor development.80 Another negative regulator of
STAT3 is SOCS3, a member of the suppressor of cytokine
signaling (SOCS) family that is often downregulated in human
cancers.81 Conditional deletion of Socs3 gene in hepatocytes
results in prolonged activation of STAT3 and accelerated
HCC development.82–84
Inflammation and the Switch in TGFb Function from a TS
to a Metastasis Promoter
Transforming growth factor b (TGFb) is both a TS and a tumor
promoter, but the mechanisms underlying this switch in
function are poorly understood. Recent studies suggest that
inflammation may have an instrumental role in this pro-
cess.85,86 TGFb has potent anti-inflammatory activity; loss or
downregulation of TGFb signaling induces inflammatory cell
infiltration.85,86 Specific deletion of Tgfbr2 in different epithelial
cells including mammary, pancreatic, intestinal, colon, and
head and neck squamous cell carcinomas, accelerates
malignant progression and metastasis through effects on
inflammation and the TME.86 Deletion of SMAD4 in colon
epithelial cells results in an increased recruitment of CCR1þ
myeloid cells (CD34þ ) that promote tumor invasion.87
Inactivation of TGFb signaling in CAFs also results in
expression of proinflammatory genes whose products pro-
mote tumor development.58,59 Deletion of SMAD4 in T
lymphocytes increases expression of IL-5, IL-6, and IL-13,
and results in tumor infiltration with inflammatory cells,
thereby promoting development of gastrointestinal carcino-
mas.88 However, it should be noted that in PCa, inactivation of
TGFb signaling in T cells resulted in tumor rejection.89
Curiously, epithelial-specific deletion of Smad4 did not result
in the aforementioned forestomach tumor phenotype.88
Furthermore, TGFb signaling is needed for CAF activation in
PCa and production of chemokines, such as CXCL13, that
recruit pro-tumoral B lymphocytes (Ammirante et al, manu-
script in preparation) (Figure 2). Indeed, CXCL13 expression
was found to correlate with clinical grade in human PCa.90
Moreover, TGFb may have an important role in the pre-
metastatic lung through S100A8 and S100A9, and Mac1þ
myeloid cell recruitment.91 These data underscore the
context-dependent nature of TGFb signaling in cancer and
its complexity.
Some of the effects of TGFb on inflammation and the TME
may be exerted through NF-kB. For instance, TGFb1
negatively regulates NF-kB activation through SMAD7,92
thus blocking proinflammatory TNF signals.93 Mice deficient
in SMAD3 and infected with Helicobacter develop colon
cancer due to increased inflammation.94 In TGFb1-deficient
mice, inflammation causes precancerous lesions to progress
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into colon cancer.95 In addition, TGFb cross-talks with
inflammatory pathways through modulation of IL-1 signal-
ing.96 However, contradictory to these observations, over-
expression of TGFb1 in HNSCC epithelial cells results in
inflammation, angiogenesis, and hyperproliferation.97 It is
unclear what underlies these different observations, or the
mechanisms that account for the proinflammatory effects of
TGFb. It is possible that TGFb simply exerts its proinflamma-
tory effects through chemokine production.98
Some of our work reveals that TGFb regulates production of
chemokine/chemokine receptors that are important for
inflammatory cell recruitment. This includes stromal-derived
factor 1 (SDF-1 or CXCL12), which mediates its effects
through CXCR4, a receptor that is highly expressed on
putative stem and progenitor cells.41,99 TGFb also sup-
presses CXCL1 and CXCL5, and inhibition of TGFb signaling
in cancer cells significantly increases expression of both
chemokines.85 These chemokines are responsible for the
recruitment of Gr-1þCD11bþ myeloid cells to the TME,
where they produce large quantities of matrix metallopro-
teases. Several MMPs including MMP2 and MMP9 are
important in the proteolytic activation of TGFb. Interestingly,
tumors with inactivated TGFb signaling produce significantly
higher levels of TGFb1 than control tumors, probably due to
increased infiltration of Gr-1þCD11bþ myeloid cells
(Figure 3). Importantly, myeloid-specific inactivation of TGFb
signaling inhibited cancer metastasis.100 These data suggest
that TGFb signaling in cancer epithelial cells functions as TS
through inhibition of inflammation, whereas myeloid TGFb
signaling in immature myeloid cell is metastasis promoting.
Clinical Correlations and Therapeutic Implications
The targeting of the inflammatory TME may be an effective
therapeutic option for patients whose cancers display
inactivation or decreased expression of TS genes that have
anti-inflammatory activity. As discussed above, inactivation or
downregulation of certain TS genes can result in increased
infiltration of inflammatory/immune cells and CAFs into the
TME. As this process can make important contributions to
cancer development and progression, we suggest that it
represents an attractive target for therapeutic intervention.
With the exception of compounds that target the Mdm2:p53
interaction,101 it is difficult or even impossible to design small
molecules that directly restore TS function. However, there is
ample evidence for the association between TS loss and
enhanced tumoral inflammation, which can be targeted by
various auto-inflammatory drugs. Several targeting opportu-
nities are envisioned (Figure 4), including IKKb or IKKa
inhibitors, metformin, as well as NSAIDs. In addition,
neutralizing antibodies and antagonists may offer additional
options to inhibit the inflammatory TME and enhance
antitumor immunity. Furthermore, cell type-specific targeting
may also provide alternative, including tumor-associated
macrophages,102,103 Gr-1þCD11bþ immature myeloid cells
or myeloid-derived suppressor cells,100,104 and B cells.61 This
is demonstrated in case of TGFb, in which myeloid-specific
deletion of TGFb signaling diminished cancer metastasis in a
number of mouse models (Figure 2).100
Clinical studies support strategies aimed at inflammation
and its consequences. For example, a study of 833 patients
with primary breast carcinoma revealed a strong association
between p53 mutations and increased VEGF expression,7
thus such patients may respond to inhibitors of VEGF
synthesis and signaling. As VEGF family members are
expressed by tumor-infiltrating macrophages,8 targeting
inflammation may provide additional therapeutic options.
Another retrospective study of HNSCC suggested that p53
suppresses inflammation through its effect on NF-kB activity
and gene expression.105 Stable cell lines expressing
the R175H, R273H, or D281G mutant forms of p53 exhibit
loss of drug sensitivity due to activation of alternative
Figure 2 Different mechanisms involving TME components contribute to T-cell tolerance and drug resistance in PCa. Androgen ablation in the TRAM mouse model
induces cancer cell death/hypoxia and myofibroblast transdifferentiation (CAF). CAFs produce high levels of TGFb and suppress host immunity by promoting Treg function
and suppressing CTL activation. In addition, CAFs produce chemokines such as CXCL13, and recruit LT-producing B cells, a process dependent on TGFb signaling in CAFs.
Pro-tumorigenic B cells produce LT and immune-suppressive factors that have an important role in resistance of androgen ablation and chemotherapy
TS suppresses tumor-associated inflammation
L Yang and M Karin
1682
Cell Death and Differentiation
NF-kB2 signaling.106 Targeting the connection between p53
and NF-kB may increase chemo-sensitivity and reduce
associated inflammation, and it may be done through the
use of IKKb or IKKa inhibitors. Drugs that inhibit inflammation
may restore the anti-inflammatory properties of TS and
facilitate tumor regression by enhancing antitumor immunity.
Several existing drugs may be considered as candidates for
such an approach, along with more classical or targeted
anticancer therapies. Metformin, a widely prescribed
antidiabetic drug, has documented anti-inflammatory proper-
ties. When used in postmenopausal women with type II
diabetes, metformin may reduce the incidence of invasive
breast cancer.107 Aspirin demonstrates strong preventive
effects in many different cancers.108 CXCL13 antagonists or
B-cell-depleting drugs may prevent the development of
castrate resistant PCa.61 Unlike conventional chemothera-
peutic agents, radiation therapy, and targeted therapies, the
inhibition of tumoral inflammation may avoid the all too
frequent development of drug resistance. When combined
with classic targeting strategies aimed at genetic and
epigenetic alterations in cancer cells, therapies aimed at the
inflammatory TME and enhancement of antitumor immunity
should offer more specific and efficient outcomes that, in
addition to cancer cells, also target extrinsic processes that
depend on cells with stable genomes, devoid of gate keeper
mutations. However, a major challenge is to differentiate host-
protective acute inflammation from tumor-promoting chronic
inflammation as well as the opposing and hard to predict
outcomes of signaling network modulation, such as TGFb
systems in different cells and tumor types.
Conclusions and Perspectives
Suppression of inflammatory cytokine/chemokine production
is a noncell autonomous process that contributes to overall
tumor suppression. Loss of TS function results in an
inflammatory response that is supposed to be beneficial for
cell/tissue damage repair. However, loss of TS function can
also have deleterious effects on the tissue and tumor
microenvironment. The synergy between an altered micro-
environment and the genetic alterations that are directly
acquired by cancer cells allows these cells to evade various
tumor surveillance mechanisms and become fully malignant.
How can the inflammatory response be both good and bad?
The idea that processes can have such dual effects is
Figure 3 Tumor-associated inflammation is critical for converting TGFb from a TS to a metastasis promoter. Host-derived immature myeloid Gr-1þCD11bþ cells are
recruited into the TME upon deletion of Tgfbr2 in mammary carcinomas epithelial cells, through CXCL5:CXCR2 and SDF-1:CXCR4 interactions. In addition, Gr-1þCD11bþ
cells express MMPs and TGFb1, which promote tumor invasion and immune suppression. The effect of these immature myeloid cells on the TME and host immune
surveillance promotes metastatic spread and is an essential contributor to the pro-metastatic action of TGFb
Figure 4 Targeting opportunities aimed at inflammation and the TME in case of
TS loss. IKKb or IKKa inhibitors, metformin, as well as anti-inflammation drugs can
be used with conventional chemotherapeutic agents, radiation therapies, and
targeted therapies. In addition, neutralization antibodies, antagonists, and cell type-
specific targeting may offer additional options to inhibit the inflammatory TME and
enhance host antitumor immunity
TS suppresses tumor-associated inflammation
L Yang and M Karin
1683
Cell Death and Differentiation
consistent with a major evolutionary theory termed antag-
onistic pleiotropy by Williams GC.
TSs confer protection against cancer by blocking the
abnormal proliferation of cells. Loss of TS function results in
uncontrolled epithelial cell division and induction of tumor-
associated inflammation. The behavior of tumor-initiating cells
that have just lost TS function is affected by the dynamic
microenvironment in which they live, which is full of growth
factors, chemokines, inflammatory cytokines, and reactive
oxygen/nitrogen species. This environment also contains
inflammatory cells that produce factors that stimulate cancer
growth as well as immune cells that can eliminate malignant
cells. How TS nonautonomous molecular signature is
activated and maintained, and how it influences malignant
progression, as well as immune evasion are all open
questions that should be addressed in future studies. None-
theless, even with our current limited knowledge, potential
new strategies for cancer therapies can be envisioned. For
example, various auto-inflammatory drugs, IKKb or IKKa
inhibitors, metformin, as well as NSAIDs may help restore TS
function.
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